Revenue: As of FY2026 Q2, the actual value is USD 9.633 M, beating the estimate of USD 9.346 M.

EPS: As of FY2026 Q2, the actual value is USD -0.07, missing the estimate of USD -0.0433.

EBIT: As of FY2026 Q2, the actual value is USD -3.549 M.

Second Quarter 2026 Financial Results

Revenue

Cytosorbents Corporation’s revenue was $9.6 million, which was unchanged from the prior year’s period.

Gross Margin

Gross margin improved to 73% in the second quarter of 2026, up from 69% in Q1 2026 and 71% a year ago.

Operating Loss

Operating loss improved by 27% to -$2.6 million, compared to -$3.6 million in Q2 2025.

Net Loss

Net loss was -$4.4 million or -$0.07 per share, in contrast to net income of $1.9 million or $0.03 per share in Q2 2025, primarily due to the non-cash impact of changes in foreign currency translations year over year.

Adjusted Net Loss

Adjusted net loss, which excludes non-cash impacts of foreign currency translations and stock compensation, improved by 22% to -$2.8 million or -$0.05 per share, compared to an adjusted net loss of -$3.7 million or -$0.06 per share in Q2 2025.

Adjusted EBITDA Loss

Adjusted EBITDA loss, excluding non-cash foreign currency translations and stock compensation, improved by 38% to -$1.6 million, compared to a loss of -$2.6 million in Q2 2025.

Cash and Cash Equivalents

Total cash, cash equivalents, and restricted cash were approximately $5.9 million on June 30, 2026, down from $6.3 million at March 31, 2026.

Cash Burn

Total cash burn in the second quarter was reduced to $0.4 million, including approximately $0.2 million in restructuring-related payments. Operating cash burn, excluding restructuring payments, was reduced to $200,000.

Operational Metrics

Revenue performance was driven by 16% growth in distributor and strategic partner sales and 9% growth in direct sales outside of Germany. This was offset by a 24% decrease in Germany sales due to a smaller sales force. Cytosorbents Corporation has reduced its workforce by approximately 23% since September 2025.

Outlook / Guidance

Cytosorbents Corporation expects to achieve operating cash flow breakeven in the second half of 2026 and plans to expand its German sales team by early 2027. The company is pursuing FDA marketing approval for DrugSorb-ATR and anticipates a new De Novo application for the Brilinta® program in early 2027. Additionally, strategic options for HemoDefend-BGA are being explored, including partnerships and government funding, following positive FDA feedback.